Literature DB >> 22541662

Uveal melanoma: molecular pattern, clinical features, and radiation response.

Michael C Chappell1, Devron H Char, Tia B Cole, J William Harbour, Kavita Mishra, Vivian K Weinberg, Theodore L Phillips.   

Abstract

PURPOSE: To characterize the clinical spectrum of class 1 and class 2 uveal melanomas and their relationship with intraocular proton radiation response.
DESIGN: Masked retrospective case series of uveal melanoma patients with fine needle biopsy-based molecular profiles.
METHODS: A total of 197 uveal melanoma patients from a single institution were analyzed for pathology, clinical characteristics, and response to radiation therapy.
RESULTS: A total of 126 patients (64%) had class 1 tumors and 71 (36%) had class 2 tumors. Patients with class 2 tumors had more advanced age (mean: 64 years vs 57 years; P = .001), had thicker initial mean ultrasound measurements (7.4 mm vs 5.9 mm; P = .0007), and were more likely to have epithelioid or mixed cells on cytopathology (66% vs 38%; P = .0004). Although mean pretreatment and posttreatment ultrasound thicknesses were significantly different between class 1 and class 2 tumors, there was no difference in the mean change in thickness 24 months after radiation therapy (mean difference: class 1 = -1.64 mm, class 2 = -1.47; P = .47) or in the overall rate of thickness change (slope: P = .64). Class 2 tumors were more likely to metastasize and cause death than class 1 tumors (DSS: P < .0001).
CONCLUSIONS: At the time of radiation therapy, thicker tumors, epithelioid pathology, and older patient age are significantly related to class 2 tumors, and class 2 tumors result in higher tumor-related mortality. We found no definitive clinical marker for differentiating class 1 and class 2 tumors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541662      PMCID: PMC4966158          DOI: 10.1016/j.ajo.2012.02.022

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  27 in total

Review 1.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 2.  Effect of senescence on macrophage polarization and angiogenesis.

Authors:  Dru S Dace; Rajendra S Apte
Journal:  Rejuvenation Res       Date:  2008-02       Impact factor: 4.663

3.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

4.  Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens.

Authors:  Michael D Onken; Lori A Worley; Rosa M Dávila; Devron H Char; J William Harbour
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

5.  Detection of M2-macrophages in uveal melanoma and relation with survival.

Authors:  Inge H G Bronkhorst; Long V Ly; Ekaterina S Jordanova; Johannes Vrolijk; Mieke Versluis; Gregorius P M Luyten; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-03       Impact factor: 4.799

6.  Prognostic factors in choroidal and ciliary body melanomas.

Authors:  H F Shammas; F C Blodi
Journal:  Arch Ophthalmol       Date:  1977-01

7.  Integrative genomic analysis of aneuploidy in uveal melanoma.

Authors:  Justis P Ehlers; Lori Worley; Michael D Onken; J William Harbour
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  Diagnostic modalities in choroidal melanoma.

Authors:  D H Char; R D Stone; A R Irvine; J B Crawford; G F Hilton; L I Lonn; A Schwartz
Journal:  Am J Ophthalmol       Date:  1980-02       Impact factor: 5.258

9.  Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Erica Person; Devron H Char; Anne M Bowcock; J William Harbour
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

10.  Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors.

Authors:  J M Seddon; L Polivogianis; C C Hsieh; D M Albert; J W Gamel; E S Gragoudas
Journal:  Arch Ophthalmol       Date:  1987-06
View more
  16 in total

1.  Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height.

Authors:  Kishan Gupta; Colin A McCannel; Mitchell Kamrava; James Lamb; Robert D Almanzor; Tara A McCannel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-24       Impact factor: 3.117

2.  Response to "Comparison of Gene Expression Profiling and Chromosome 3 Analysis by Fluorescent in situ Hybridization and Multiplex Ligation Probe Amplification in Fine-Needle Aspiration Biopsy Specimens of Uveal Melanoma".

Authors:  Kristen M Plasseraud; Federico A Monzon
Journal:  Ocul Oncol Pathol       Date:  2017-09-21

3.  CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.

Authors:  Duncan E Berry; Amy C Schefler; Michael I Seider; Miguel Materin; Sandra Stinnett; Prithvi Mruthyunjaya
Journal:  Retina       Date:  2018-11-08       Impact factor: 4.256

4.  Gene expression profiling and regression rate of irradiated uveal melanomas.

Authors:  Rajesh C Rao; Mehnaz Khan; Shahed N Badiyan; J William Harbour
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-03       Impact factor: 1.300

5.  Gene Expression Profiling in Uveal Melanoma: Five-Year Prospective Outcomes and Meta-Analysis.

Authors:  Thomas M Aaberg; Kyle R Covington; Tony Tsai; Yevgeniy Shildkrot; Kristen M Plasseraud; Katherina M Alsina; Kristen M Oelschlager; Federico A Monzon
Journal:  Ocul Oncol Pathol       Date:  2020-07-06

6.  Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status.

Authors:  Sachin M Salvi; Hassan A Aziz; Suhail Dar; Nakul Singh; Brandy Hayden-Loreck; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2016-10-29

Review 7.  Disparities in Uveal Melanoma: Patient Characteristics.

Authors:  Erin E Nichols; Ann Richmond; Anthony B Daniels
Journal:  Semin Ophthalmol       Date:  2016-04-29       Impact factor: 1.975

8.  Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism.

Authors:  Royce W S Chen; J William Harbour
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-09-12       Impact factor: 3.117

9.  Extrascleral Tumor Extension Associated with Localized Scleral Melt following Plaque Brachytherapy for Uveal Melanoma: Clinical and Histologic Findings.

Authors:  Chau M Pham; Steven M Couch; George J Harocopos
Journal:  Ocul Oncol Pathol       Date:  2017-08-23

10.  Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5.

Authors:  Christina Binder; Prithvi Mruthyunjaya; Amy C Schefler; Michael I Seider; Richard Crilly; Arthur Hung; Sheridan Meltsner; Yvonne Mowery; David G Kirsch; Bin S Teh; Richard L S Jennelle; Matthew T Studenski; Wu Liu; Choonik Lee; James A Hayman; Brian Kastner; Michael Hadsell; Alison H Skalet
Journal:  Ocul Oncol Pathol       Date:  2019-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.